Table 2.

Responses

	Univariate OR (95% CI)	p	Multivariate OR (95% CI)	p
Age at AML relapse (per year)	0.96 (0.92–0.99)	0.02	0.8 (0.8–0.9)	0.002
Length from AML diagnosis to relapse (per month)	1.18 (1.075–1.3)	0.0006	1.3 (1.0–1.6)	0.004
Cycles of consolidation therapy prior to relapse (per cycle)	1.88 (1.03–3.4)	0.0397	1.8 (0.7–4.4)	0.2
Percent blasts at AML relapse	1.01 (0.997–1.038)	0.0895	1.0 (1.0–1.1)	0.002
Hemoglobin at AML relapse	1.21 (0.966–1.527)	0.0966	1.7 (1.0–3.1)	0.04
Platelet count at AML relapse	1.0 (0.99–1.0)	0.5103	1.0 (1.0–1.03)	0.003
Primary versus secondary AML	2.5 (0.29–21)	0.39
WBC at AML relapse	1.0 (0.98–1.0)	0.8661
Cytogenetic risk at AML relapse
Favorable versus unfavorable	13 (1.4–133)	0.02
Intermediate versus unfavorable	2.8 (0.5–14)	0.6

OR, odds ratios; with OR >1.0 corresponding to increased odds of the occurrence of CR or CRi; CI, confidence interval.